According to published data, the effectiveness of the drug, tested during the third phase of clinical trials on 19.8 thousand volunteers, was set at 91.6%.
"Thus, Sputnik V is more effective than vaccines from AstraZeneca or Johnson & Johnson", - said Ertle Hildegund, MD, professor at the Center for Vaccines and Immunotherapy at the Wistar Institute in the United States. Her words are quoted in a press release from the Russian Direct Investment Fund.
Commenting on the research results, Hildegund added that the Russian vaccine protects 100% against severe illness and death. "And this is the most important parameter. We can all cope with a mild runny nose, the main thing is not to be in the hospital and not have serious complications", she said. Hildegund emphasized that the Russian vaccine, which is as effective as its foreign counterparts produced by Pfizer and Moderna, has an undoubted advantage over them - the Russian vaccine does not need to be stored at extremely low temperatures, which means it can be kept in an ordinary refrigerator. which simplifies the process of using it.
After the introduction of the first dose of the vaccine, the effectiveness of the drug is set at 87.6%, the study notes. With the introduction of the second dose - at the level of 91.6%. At the same time, the results of a study of the drug on pensioners showed an efficiency of 91.8%. The number of antibodies that a person produces after vaccination is 1.3-1.5 times higher than that of those who have had a natural coronavirus. Moreover, in 94% of cases, the side effects of this vaccine were mild and were associated with headaches and mild colds.
Now the drug is already registered in 16 countries of the world: in Russia, Belarus, Serbia, Argentina, Bolivia, Algeria, Palestine, Venezuela, Paraguay, Turkmenistan, Hungary, UAE, Iran, Republic of Guinea, Tunisia and Armenia.